KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Bio-Rad Laboratories (BIO) EBITDA (2016 - 2025)

Historic EBITDA for Bio-Rad Laboratories (BIO) over the last 17 years, with Q4 2025 value amounting to -$118.9 million.

  • Bio-Rad Laboratories' EBITDA fell 30394.51% to -$118.9 million in Q4 2025 from the same period last year, while for Dec 2025 it was $47.2 million, marking a year-over-year decrease of 8244.7%. This contributed to the annual value of $47.2 million for FY2025, which is 8245.35% down from last year.
  • Bio-Rad Laboratories' EBITDA amounted to -$118.9 million in Q4 2025, which was down 30394.51% from $65.3 million recorded in Q3 2025.
  • In the past 5 years, Bio-Rad Laboratories' EBITDA registered a high of $156.8 million during Q3 2021, and its lowest value of -$118.9 million during Q4 2025.
  • Moreover, its 5-year median value for EBITDA was $92.8 million (2022), whereas its average is $81.8 million.
  • In the last 5 years, Bio-Rad Laboratories' EBITDA surged by 14116.19% in 2021 and then crashed by 30394.51% in 2025.
  • Quarter analysis of 5 years shows Bio-Rad Laboratories' EBITDA stood at $117.9 million in 2021, then increased by 0.65% to $118.7 million in 2022, then decreased by 19.66% to $95.3 million in 2023, then crashed by 38.84% to $58.3 million in 2024, then plummeted by 303.95% to -$118.9 million in 2025.
  • Its EBITDA stands at -$118.9 million for Q4 2025, versus $65.3 million for Q3 2025 and $77.1 million for Q2 2025.